Benzgalantamine

Last updated

Benzgalantamine
Benzgalantamine.svg
Clinical data
Trade names Zunveyl
Other namesALPHA-1062
AHFS/Drugs.com Monograph
MedlinePlus a624044
License data
Routes of
administration 		By mouth
Drug class Cholinesterase inhibitor
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C24H25NO4
Molar mass 391.467 g·mol−1
3D model (JSmol)
  • COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2
  • InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1
  • Key:JKVNJTYHRABHIY-WXVUKLJWSA-N

Benzgalantamine, sold under the brand name Zunveyl, is a medication used for the treatment of mild to moderate dementia of the Alzheimer's type. [1] It is a cholinesterase inhibitor. [1] Benzgalantamine is a prodrug of galantamine. [1]

Contents

The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. [1]

Benzgalantamine was approved for medical use in the United States in July 2024. [1] [2] [3]

Medical uses

Benzgalantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. [1] [2]

Side effects

The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. [1]

Society and culture

Benzgalantamine was approved for medical use in the United States in July 2024. [1] [2]

Names

Benzgalantamine is the international nonproprietary name. [4]

References

  1. 1 2 3 4 5 6 7 8 9 "Zunveyl- benzgalantamine tablet, delayed release". DailyMed. 8 August 2024. Retrieved 15 August 2024.
  2. 1 2 3 fda.gov
  3. ↑ "Alpha Cognition's Oral Therapy Zunveyl Receives FDA Approval to Treat Alzheimer's Disease" (Press release). Alpha Cognition. 29 July 2024. Archived from the original on 4 August 2024. Retrieved 4 August 2024– via Business Wire.
  4. ↑ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl: 10665/363551 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.